HACKENSACK, N.J., Feb. 3, 2020 /PRNewswire/ -- Hackensack Meridian Hackensack University Medical Center announced today that it is the first hospital in the nation to successfully implant the world's first heart failure neuromodulation device, BAROSTIM NEO™. This innovative technology is an effective alternative for patients with Congestive Heart Failure (CHF) who are ineligible for other forms of therapy such as Cardiac Resynchronization Therapy (CRT).

"Hackensack University Medical Center is on the forefront of delivering cutting-edge treatment for our patients," said Mark D. Sparta, FACHE, president and chief hospital executive, Hackensack University Medical Center and executive vice president of Population Health, Hackensack Meridian Health. "We are proud to be the first hospital in the nation to offer this life-saving, innovative device to improve the quality of life for heart failure patients."

Patients with CHF suffer from shortness of breath and are limited to mild daily activity. Utilizing the nervous system to treat cardiovascular disease, BAROSTIM NEO offers a groundbreaking treatment alternative for CHF patients. This state-of-the-art device has the unique ability to improve heart performance, reduce hospital readmissions and reduce the amount of medications patients take. It also increases mobility and reduces the risk of infection long-term for patients because it does not have a pump or catheter like other devices.
"Hackensack University Medical Center is excited to be the first hospital in the country to offer our heart failure patients a promising solution," said Joseph E. Parrillo, M.D., Chairman, Heart and Vascular Hospital, Hackensack University Medical Center, Professor and Chair, Department of Cardiology, Hackensack Meridian School of Medicine at Seton Hall University. "By utilizing the nervous system to treat heart failure, we now have a pioneering, new way of improving cardiovascular health."

"This new, innovative technology is a promising alternative for patients suffering from heart failure," said Massimo M. Napolitano, M.D., FACS, interim chair Department of Surgery, director of Vascular Services, Hackensack University Medical Center. Dr. Napolitano has traveled all over the United States teaching other physicians how to implant BAROSTIM NEO. "Once the device is implanted, complications from the implant procedure are minimal and the patient's mobility is greatly increased."

Cardiology Homepage